Patients with metastatic breast cancer using bevacizumab as a treatment: Is there still a role for it?

Current Treatment Options in Oncology

Volumn 13, Issue 2, 2012, Pages 249-262

  Lohmann, Ana Elisa ^a   Chia, Stephen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Anti Angiogenesis; Bevacuzimab; Metastatic breast cancer; VEGF

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERIBULIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FULVESTRANT; GEMCITABINE; IMETELSTAT; LAPATINIB; LETROZOLE; NAVELBINE; PACLITAXEL; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ARTICLE; BLEEDING; BRAIN CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DISTANT METASTASIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSAL BLEEDING; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CARDIOTOXINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863726318     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-012-0181-9     Document Type: Article

References (73)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61 (2):69-90.
4. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet. 2011;378 (9801):1461-84.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365(9472):1687-717.
6. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, et al. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst. 1992;84(16):1266-72.
7. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer Jr CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366-73.
8. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16(10):3439-60.
9. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB,Wong Y, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). ASCO Meeting Abstracts 2009 June 08;27(15S):543.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98 (19):10869-74.
12. Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52(1-3):65-77.
13. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002;20(12):2812-23.
14. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980-6.
15. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950-7.
16. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group StudyMA8. JClinOncol. 2000;18 (12):2385-94.
17. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit? Eur J Cancer. 2008;44(16):2350-6.
18. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76.
19. Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: A phase III trial of Bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;20:4966-72.
20. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of Bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(20):3239-47.
21. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without Bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent ormetastatic breast cancer. J Clin Oncol. 2011;29(10):1252-60.
22. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer. 2002;38(12):1564-79.
23. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815-21.
24. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795-803.
25. Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur Cytokine Netw. 2009;20(4):158-63. This article summarizes the biological and molecular characteristics of VEGF and its role in tumor angiogenesis. This paper describes the history of VEGF and clinical trials with VEGF inhibitors in patients with cancer as well.
26. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-27.
27. Zerbini G, Lorenzi M, Palini A. Tumor angiogenesis. N Engl J Med. 2008 author reply 764; Aug 14;359 (7):763; author reply 764.
28. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549-60.
29. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994;269(41):25646-54.
30. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A. 1998;95 (20):11709-14.
31. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255(5047):989-91.
32. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001;276(29):26969-79.
33. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87(8):3336-43.
34. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta. 2010;1806(1):108-21.
35. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-9.
36. Miller KD, Chap LI,Holmes FA, CobleighMA,Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23 (4):792-9.
37. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30(5 Suppl 16):117-24.
38. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, et al. RIBBON-2: A randomized, doubleblind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-Negative metastatic breast cancer. J Clin Oncol. 2011;29 (32):4286-93.
39. Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Programand abstracts of the 34th Annual San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, Texas. Abstract S4-8.
40. Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, et al. Sunitinib plus paclitaxel versus Bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial. Clin Breast Cancer. 2011;11(2):82-92.
41. O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, et al. A meta-Analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010;28(15 SUPPL. 1);28(15 SUPPL. 1):ate of Pubaton: 20 May 2010. This importantmeta-Analysis evaluates three randomized trials (E2100, AVADO, and RIBBON-1) in patients with MBC that received bevacizumab plus first-line chemotherapy regimens. The study documents the gain in progress-free-survival, and the lack of significant improvement in overall survival.
42. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Bevacizumab in metastatic breast cancer: A meta-Analysis of randomized controlled trials. Breast Cancer Res Treat. 2010;122 (1):1-7.
43. Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, et al. Magnitude of risks and benefits of the addition of Bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res. 2011;30:54.
44. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-92.
45. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with Bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26(30):4899-905.
46. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline-And taxane-refractory breast cancer. J Chemother. 2008;20(5):632-9.
47. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation. 1995;91(3):755-63.
48. Yardley DA, Burris 3rd HA, Clark BL, Shipley D, Rubin M, Barton Jr J, et al. Hormonal therapy plus Bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: A phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer. 2011;11 (3):146-52.
49. Traina TA, Rugo HS, Caravelli JF, Patil S, Yeh B, Melisko ME, et al. Feasibility trial of letrozole in combination with Bevacizumab in patients with metastatic breast cancer. J Clin Oncol. 2010;28 (4):628-33.
50. De la Haba-Rodriguez JR, von Minckwitz G, Martin M. Phase III tril evaluating the addition of Bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: The Lea Study. Program and abstracts of the 34th Annual San Antonio Breast Cancer Symposium; December 6-10, 2011; San Antonio, Texas. Abstract OT3-01-15.
51. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with Bevacizumab. J Clin Oncol. 2011;29(6):632-8.
52. Bernaards C, Hegde P, Chen D, Holmgren E, Zheng M, Jubb AM, et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, nonsmall cell lung, and renal cell cancers: Analysis of phase III studies. ASCO Meeting Abstracts 2010 June 14;28(15suppl):10519.
53. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus Bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26 (28):4672-8.
54. Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). ASCO Meeting Abstracts 2010 June 14;28(15suppl):3039.
55. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol. 2010;11(12):1172-83. This interesting review discusses clinical, radiological, and molecular markers of bevacizumab efficacy. It analyses some predictive value for hypertension, vascular imaging, and polymorphisms affecting components of the vascular endothelial growth factor pathway in patients receiving bevacizumab.
56. Mrozek E, Lustberg MB, Knopp MV, Spigos DG, Yang X, Houton LA, et al. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). J Clin Oncol. 2010;28(15 SUPPL. 1);28(15 SUPPL. 1): Ate of Pubaton: 20 May 2010.
57. MancusoMR, Davis R,Norberg SM,O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610-21.
58. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-Term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15 (3):232-9.
59. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15 (3):220-31.
60. Miles D, Harbeck N, Escudier B, Hurwitz H, Saltz L, Van Cutsem E, et al. Disease course patterns after discontinuation of Bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol. 2011;29 (1):83-8.
61. Von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. Integrating Bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol. 2011;22(2):301-6.
62. Bear H., Tang Gong, Rastogi. NSABP Protocol B-40: The effect on PCR of Bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy ASCO Meeting Abstracts 2011 June Jun 23, 2011: LBA1005.
63. Ranpura V, Hapani S, Wu S. Treatment-related mortality with Bevacizumab in cancer patients: A metaanalysis. JAMA. 2011;305(5):487-94.
64. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation. Eur J Cancer. 2009;45(8):1397-406. This important article evaluates the addition of bevacizumab to paclitaxel in MBC patients. It shows that bevacizumab is expensive given the clinical benefit in terms of quality-Adjusted life years gained.
65. Montero AJ, Gluck S, Lopes GdL. The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. ASCO Meeting Abstracts 2011 June 09;29(15suppl):6060.
66. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121(1):121-31.
67. Moss J, Stevens M, Birk S, Westberry K, Romond E, Shelton B, et al. Abstract P4-02-19: A phase II study of adding the multikinase inhibitor sorafenib to existing endocrine therapy in patients with metastatic estrogen receptor positive breast cancer. Cancer Res. 2011;70(24 Supplement):P4-02-19.
68. Luu T, Frankel P,ChungC,Mortimer J,Hurria A, Somlo G. Abstract P6-12-07: Phase II trial of vinorelbine and sorafenib in Metastatic Breast Cancer (MBC). Cancer Res. 2011;70(24 Supplement):P6-12-07.
69. Bondarde S, Kaklamani V, Prasad Sahoo T, Lokanatha D, Raina V, JainM, et al. Abstract P2-16-03: Sorafenib in combination with paclitaxel as a first-line therapy in patients with locally recurrent or metastatic breast cancer: Overall survival results from a double-blind, randomized, placebo-controlled, phase 2b trial. Cancer Res. 2011;70(24 Supplement):P2-16-03.
70. Gomez P, Roche H, Costa F, Segalla J, Pinczowski H, Ciruelos E, et al. Abstract P2-16-01: Overall survival data from SOLTI-0701: A multinational, doubleblind, placebo-controlled, randomized phase 2b study evaluating the oral combination of sorafenib and capecitabine in patients with locally advanced or metastatic HER2-Negative breast cancer. Cancer Res. 2011;70(24 Supplement):P2-16-01.
71. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, et al. Motesanib, or open-label Bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011;12(4):369-76.
72. Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011;29(18):2459-65.
73. Phase III study of Docetaxel + Ramucirumab or placebo in breast cancer. Available at :http://www.liferaft-groups.org. Accessed December 13, 2011.